Results 81 to 90 of about 58,710 (306)
Chronic allopurinol treatment during the last trimester of pregnancy in sows: effects on low and normal birth weight offspring. [PDF]
PLoS ONE, 2014 Low-birth-weight (LBW) children are born with several risk factors for disease, morbidity and neonatal mortality, even if carried to term. Placental insufficiency leading to hypoxemia and reduced nutritional supply is the main cause for LBW. Brain damage
Elise T Gieling +9 more
doaj +1 more source
Allopurinol induced erythroderma
Indian Journal of Pharmacology, 2013 Allopurinol, a widely prescribed urate lowering agent is responsible for various adverse drug reactions, including erythroderma. A 45-year-old male patient was admitted with the complaints of fever, redness and scaling all over the body after 3-4 weeks of allopurinol treatment for asymptomatic hyperuricemia.
Geeta Sharma, Dinesh Chandra Govil
openaire +4 more sources
Potential role of NADPH-oxidase in early steps of lead-induced oxidative burst in Vicia faba roots [PDF]
, 2008 The mechanism of oxidative burst induced by lead in Vicia faba excised roots was investigated by luminol-dependent chemiluminescence. Results showed that lead triggered a rapid and dose-dependent increase in chemiluminescence production.
Cecchi, Marie +5 more
core +3 more sources
Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test
Clinical Pharmacology &Therapeutics, EarlyView.There is increasing attention on the clinical utility and value of pharmacogenetic (PGx) testing to individualize medication management. Most clinical practice guidelines from medical professional societies do not recommend routine PGx testing, with a few key exceptions.
James M. Stevenson +4 more
wiley +1 more source
Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study. [PDF]
PLoS ONE, 2014 Previous studies have shown an association between gout and/or hyperuricemia and a subsequent increase in cardiovascular disease (CVD) outcomes. Allopurinol reduces vascular oxidative stress, ameliorates inflammatory state, improves endothelial function,
Victor C Kok +4 more
doaj +1 more source
Crystals, 2022 Allopurinol is a relatively water-insoluble drug and, consequently, its efficacy was frequently limited by the dissolution or solubility phenomena.
Salal Hasan Khudaida +3 more
doaj +1 more source
Metabolic Control, Quality of Life, and Body Image in Patients with Glycogen Storage Disease Type Ia [PDF]
, 2019 Glycogen storage disease is a group of inborn errors of metabolism, with type Ia being the most common form of the disorder. Glycogen storage disease type Ia (GSDIa) is a multisystemic condition in which individuals have various complications secondary ...
Bream, Alexa
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes.
Bella D. Ianni +3 more
wiley +1 more source
Arthritis & Rheumatology, 2018 Recently, the US Food and Drug Administration (FDA) issued a public safety alert, responding to the results of the now‐published Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities (CARES) trial.
Hyon K. Choi +4 more
semanticscholar +1 more source
Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. [PDF]
, 2019 ObjectiveLesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI. The aim of the study was
Baumgartner, Scott +8 more
core +1 more source